Your Cart is Empty

Back To Shop

Ultramix 300mg/ml 10 ml (Trenbolone Enanthate, Drostanolone Propionate, Testosterone  Enanthate) – Medical Pharma Steroid USA


Trenbolone Enanthate

(17β)-3-Oxoestra-4,9,11-trien-17-yl heptanoate
C25H34O3 = 382.2
CAS — 10161-33-8

Ultramix 300mg/ml 10 ml (Trenbolone Enanthate, Drostanolone Propionate, Testosterone  Enanthate) – Medical Pharma Steroid USA


Ultramix Pharmacopoeias

USP 31 (Trenbolone Enanthate). Solution oily transparent color from light yellow to yellow, with characteristic odor. It should be stored at room temperature.

Enantato de Testosterona; NSC-17591; Testosteron enantát; Testostérone, enantate de; Testosterone Enanthate; Testosterone Heptanoate; Testosterone Heptylate; Testosteronenantat; Testosteroni enantas; Testosteronienantaatti; Testosterono enantatas; Testosteronu enantan; Tesztoszteronönantát. 3-Oxoandrost-4-en-17β-yl heptanoate; 17β-Hydroxyandrost-4-en-3-one heptanoate.

C26H40O3 = 400.6.
CAS — 315-37-7.
ATC — G03BA03.
ATC Vet — QG03BA03.

USP 31 (Testosterone Enanthate). A white or creamy-white crystalline powder. It is odourless or has a faint odour characteristic of heptanoic acid. Insoluble in water; very soluble in ether; soluble in vegetable oils. Protect from light.

Drostanolone Propionate Compound 32379; Dromostanolone Propionate  (USAN); Drostanolone, Propionate de; Drostanoloni Propionas; 2α-Methyldihydrotestosterone Propionate; NSC-12198; Propionato de drostanolona. 17β-Hydroxy-2α-methyl-5α-androstan-3-one propionate.

C23H36O3 = 360.5.
CAS — 58-19-5 (drostanolone); 521-12-0 (drostanolone propionate).

Ultramix: 300mg

⦁ 100 mg / ml Trenbolone enanthate
⦁ 100 mg / ml Drostanolone propionate
⦁ 100 mg / ml Testosterone Enanthate

Pharmacologic category

Androgen combination

Dosing and administration:

Deep intramuscular injection. 300mg injected IM every 3-5 days for duration of 4-8 weeks.

Dosing: Renal impairment

There are no dosage adjustments provided in manufacturers. Use with caution; may enhance edema formation.

Dosing: Hepatic impairment

There are no dosage adjustments provided in manufacturer’s labeling. Use with caution; may enhance edema formation. Ripex is contraindicated in serious hepatic disease.


Trenbolone acetate, Drostanolone propionate and Testosterone Enanthate have been used as anabolic agents in practice.
It is administered through deep intramuscular.


Store in airtight containers at room temperature.


Hypersensitivity to trenbolone, drostanolone propionate, testosterone enanthate benzyl alcohol or any component of the formulation.
Men with carcinomas of the breast or with known or suspected carcinomas of the prostate; women who are or may become pregnant.
Documentation of allergenic cross-reactivity for androgens is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.


⦁ Gynecomastia: May cause gynecomastia.

⦁ Hepatic effects: Prolonged use and/or high doses may cause peliosis hepatis or liver cell tumors, which may not be apparent until liver failure or intra-abdominal hemorrhage develops. Discontinue in case of cholestatic hepatitis with jaundice or abnormal liver function tests.

⦁ Venous thromboembolism: Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), have been reported with testosterone products. Evaluate patients with symptoms of pain, edema, warmth, and erythema in the lower extremity for DVT and those with acute shortness of breath for PE. Discontinue therapy if a venous thromboembolism is suspected.

Disease related concerns:

⦁ Breast cancer: Use with caution in patients with breast cancer; may cause hypercalcemia by stimulating osteolysis.

⦁ Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal impairment); may cause fluid retention.

⦁ Hepatic impairment: Use with caution in patients with hepatic impairment.

Pregnancy risk factor


Category X: Studies in animals or human beings have demonstrated fetal abnormalities, or there is evidence of fetal risk based on human experience, or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.

Pregnancy considerations

Use is contraindicated in women who are or may become pregnant; masculinization of the fetus has been reported.


Excretion in breast milk unknown/not recommended

Adverse reactions

Frequency not always defined.

Cardiovascular: Hypertension (≥3%), increased blood pressure (1%), decreased blood pressure, deep vein thrombosis, edema, vasodilatation

Central nervous system: Headache (1% to ≥3%), fatigue (2%), irritability (2%), insomnia (≤2%), mood swings (≤2%), aggressive behavior (1%), taste disorder (1%), altered sense of smell (≤1%), abnormal dreams, amnesia, anxiety, chills, depression, dizziness, emotional lability, excitement, hostility, malaise, nervousness, outbursts of anger, paresthesia, seizure, sleep apnea, suicidal ideation
Dermatologic: Acne vulgaris (5%), hyperhidrosis (1%), alopecia, contact dermatitis, diaphoresis, erythema, folliculitis, hair discoloration, pruritus, seborrhea, skin rash, xeroderma.

Endocrine & metabolic: Increased plasma estradiol concentration (3%), weight gain (1%), gynecomastia (≤1%), hot flash (≤1%), change in libido, decreased gonadotropin, fluid retention, hirsutism (increase in pubic hair growth), hypercalcemia, hyperchloremia, hypercholesterolemia, hyperglycemia, hyperkalemia, hyperlipidemia, hypernatremia, hypoglycemia, hypokalemia, inorganic phosphate retention, menstrual disease (including amenorrhea).

Gastrointestinal: Diarrhea (≥3%), gastroesophageal reflux disease, gastrointestinal hemorrhage, gastrointestinal irritation, increased appetite, nausea, vomiting.

Genitourinary: Prostate specific antigen increase (5% to 11%), prostatitis (≥3%), ejaculatory disorder (1%), prostate induration (1%), spontaneous erections (≤1%), benign prostatic hypertrophy, difficulty in micturition, hematuria, impotence, irritable bladder, mastalgia, oligospermia, priapism, testicular atrophy, urinary tract infection, virilization.

Hepatic: Abnormal hepatic function tests, cholestatic hepatitis, cholestatic jaundice, hepatic insufficiency, hepatic necrosis, hepatocellular neoplasms, increased serum bilirubin, peliosis hepatis.

Hematologic & oncologic: Increased hematocrit (1% to 3%), increased hemoglobin (2%), malignant neoplasm of prostate (1%), anemia, clotting factors suppression, hemorrhage, leukopenia, polycythemia, prostate carcinoma.

Hypersensitivity: Anaphylactoid reaction, hypersensitivity reaction (including pulmonary oil microembolism).

Local: Pain at injection site (5%), erythema at injection site (1%), application site reaction (gel, solution), inflammation at injection site.

Neuromuscular & skeletal: Arthralgia (≥3%), back pain (≥3%), abnormal bone growth (accelerated), hemarthrosis, hyperkinesia, weakness.

Ophthalmic: Increased lacrimation

Renal: Increased serum creatinine, polyuria

Respiratory: Bronchitis (≥3%), nasopharyngitis (≥3%), sinusitis (≥3%), upper respiratory tract infection (≥3%), dyspnea
<1%, postmarketing, and/or case reports: Injection: Abdominal pain, abnormal erythropoiesis, abscess at injection site, allergic dermatitis, anaphylactic shock, anaphylaxis, androgenetic alopecia, angina pectoris, angioedema, asthma, breast induration, cardiac arrest, cardiac failure, cerebral infarction, cerebrovascular accident, cerebrovascular insufficiency, chest pain, chronic obstructive pulmonary disease, circulatory shock, cognitive dysfunction, confusion, coronary artery disease, coronary occlusion, cough, decreased plasma testosterone, decreased thyroxine binding globulin, decreased urinary calcium excretion, diabetes mellitus, dysuria, electrolyte disturbance, epididymitis, erectile dysfunction, hearing loss (sudden), hematoma at injection site, hepatotoxicity (idiosyncratic) (Chalasani, 2014), hyperparathyroidism, hypersensitivity angiitis, hypertriglyceridemia, hyperventilation, impaired glucose tolerance, increased gamma-glutamyl transferase, increased intraocular pressure, increased serum ALT, increased serum AST, increased serum prolactin, increased serum transaminases, increased serum triglycerides, Korsakoff’s psychosis (nonalcoholic), migraine, musculoskeletal chest pain, musculoskeletal pain, myalgia, myocardial infarction, nephrolithiasis, nipple tenderness, orgasm disturbance (male), osteopenia, osteoporosis, peripheral edema, personality disorder, pharyngeal edema, pharyngolaryngeal pain, prolonged partial thromboplastin time, prolonged prothrombin time, prostatic intraepithelial neoplasia, pulmonary embolism, pure red cell aplasia, renal colic, renal pain, respiratory distress, restlessness, reversible ischemic neurological deficit, rhinitis, sleep disorder, snoring, spermatocele, syncope, systemic lupus erythematosus, tachycardia, testicular pain, thrombocytopenia, thromboembolism, thrombosis, tinnitus, transient ischemic attacks, urinary incontinence, urolithiasis, urticaria, venous insufficiency, venous thromboembolism, vesicobullous rash, virilization (of children, following secondary exposure to topical gel [advanced bone age, aggressive behavior, enlargement of clitoris requiring surgery, enlargement of penis, increased erections, increased libido, pubic hair development]), vitreous detachment, voice disorder.

Metabolism/Transport effects

None known.

Drug interactions

Corticosteroids, Warfarin and Antidiabetic agents.

Test interactions

May suppress factors II, V, VII, and X; may increase PT; may decrease thyroxine-binding globulin and radioactive iodine uptake

Monitoring parameters

Liver function tests, cholesterol profile, hemoglobin/hematocrit; INR/PT in patients on anticoagulant therapy.

Children: Radiographs of left wrist and hand every 6 months (to assess bone maturation).

Adult females: Signs of virilization (deepening voice, hirsutism, acne, clitoromegaly); urine and serum calcium in women with breast cancer.

Dosage forms

Injectable solution – 300mg/ml in a 10ml multi-dose vial (contains benzyl alcohol)

Mechanism of action

Principal endogenous androgen responsible for promoting the growth and development of the male sex organs and maintaining secondary sex characteristics in androgen-deficient males.

Metabolism: Hepatic

Elimination: Bile (80%)

Half-life: 2 weeks.

Buy anabolis steroids online USA.


Your Cart is Empty

Back To Shop